litigation
confidence high
sentiment positive
materiality 0.80
Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%
Jazz Pharmaceuticals plc
- On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.
- Injunction prevents Avadel from seeking FDA approval or marketing Lumryz for idiopathic hypersomnia or other new indications.
- Avadel is enjoined from infringing Claim 24 of Jazz's '782 patent through February 2036, except for narcolepsy and existing patients.
- Court awarded Jazz an ongoing royalty for future narcolepsy Lumryz sales at a rate to be determined above 3.5%.
- Jazz previously won jury verdict finding '782 patent valid and damages for past Lumryz sales.